Manitex Capital Inc. does not have significant business.
+ 1 more risk
Adequate balance sheet and slightly overvalued.
Share Price & News
How has Manitex Capital's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MNX has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: MNX exceeded the Canadian Healthcare industry which returned -46.7% over the past year.
Return vs Market: MNX exceeded the Canadian Market which returned -24.8% over the past year.
Price Volatility Vs. Market
How volatile is Manitex Capital's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 weeks ago | Simply Wall StShould You Be Concerned About Manitex Capital Inc.'s (CVE:MNX) Historical Volatility?
2 months ago | Simply Wall StCould The Manitex Capital Inc. (CVE:MNX) Ownership Structure Tell Us Something Useful?
6 months ago | Simply Wall StHow Should Investors React To Manitex Capital Inc.'s (CVE:MNX) CEO Pay?
Is Manitex Capital undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate MNX's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate MNX's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: MNX is good value based on its PE Ratio (10.3x) compared to the Healthcare industry average (17.4x).
PE vs Market: MNX is poor value based on its PE Ratio (10.3x) compared to the Canadian market (10.3x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MNX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MNX is good value based on its PB Ratio (0.2x) compared to the CA Healthcare industry average (1.9x).
How is Manitex Capital forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Manitex Capital has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine Manitex Capital's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Manitex Capital competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Healthcare industry.
How has Manitex Capital performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MNX has a large one-off loss of CA$436.3K impacting its October 31 2019 financial results.
Growing Profit Margin: MNX's current net profit margins (6.1%) are lower than last year (43.1%).
Past Earnings Growth Analysis
Earnings Trend: MNX's earnings have declined by -23.6% per year over the past 5 years.
Accelerating Growth: MNX's earnings growth over the past year (128.8%) exceeds its 5-year average (-23.6% per year).
Earnings vs Industry: MNX earnings growth over the past year (128.8%) exceeded the Healthcare industry 11.4%.
Return on Equity
High ROE: MNX's Return on Equity (-7.2%) is considered low.
How is Manitex Capital's financial position?
Financial Position Analysis
Short Term Liabilities: MNX's short term assets (CA$3.8M) exceed its short term liabilities (CA$899.7K).
Long Term Liabilities: MNX's short term assets (CA$3.8M) exceed its long term liabilities (CA$541.7K).
Debt to Equity History and Analysis
Debt Level: MNX's debt to equity ratio (3.2%) is considered satisfactory.
Reducing Debt: MNX's debt to equity ratio has reduced from 6.2% to 3.2% over the past 5 years.
Debt Coverage: MNX's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if MNX's interest payments on its debt are well covered by EBIT.
What is Manitex Capital's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MNX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate MNX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MNX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MNX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MNX's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Steve Saviuk (60yo)
Mr. Steven Saviuk, also known as Steve, CA, has been Executive Chairman of the Board of Directors at Ortho Regenerative Technologies Inc. since March 06, 2019. He serves as the Chairman and Chief Executive ...
CEO Compensation Analysis
Compensation vs Market: Steve's total compensation ($USD243.45K) is above average for companies of similar size in the Canadian market ($USD158.76K).
Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.
|Chairman||no data||CA$344.07k||8.34% CA$230.6k|
|CFO & Director||10.08yrs||CA$167.50k||3.47% CA$95.8k|
|Secretary & Independent Director||19.33yrs||no data||0.17% CA$4.6k|
|Independent Director||19.33yrs||CA$1.00k||no data|
Experienced Board: MNX's board of directors are seasoned and experienced ( 19.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Manitex Capital Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Manitex Capital Inc.
- Ticker: MNX
- Exchange: TSXV
- Industry: Health Care Distributors
- Sector: Healthcare
- Market Cap: CA$2.763m
- Shares outstanding: 12.56m
- Website: https://www.manitexcapital.com
- Manitex Capital Inc.
- 16667 Hymus Boulevard
- H9H 4R9
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|MNX||TSXV (TSX Venture Exchange)||Yes||Common Shares||CA||CAD||Oct 2000|
Manitex Capital Inc. does not have significant business. It focuses on acquiring interests in life sciences, cleantech, and sustainable products/technologies companies. Previously, it was engaged in the acquisition and markets specialty pharmaceutical products, and distributes third-party pharmaceutical products, as well as holds a portfolio in marketable securities. The company is headquartered in Kirkland, Canada.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/08 03:17|
|End of Day Share Price||2020/03/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.